{"id":862,"date":"2024-08-05T23:06:36","date_gmt":"2024-08-06T06:06:36","guid":{"rendered":"https:\/\/cloudbreakpharma.com\/?p=862"},"modified":"2024-08-05T23:14:21","modified_gmt":"2024-08-06T06:14:21","slug":"santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium","status":"publish","type":"post","link":"https:\/\/cloudbreakpharma.com\/zh\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/","title":{"rendered":"\u62e8\u5eb7\u89c6\u4e91\u53ca\u53c2\u5929\u5236\u836f\u5ba3\u5e03\u5c31\u7ffc\u72b6\u80ec\u8089\u521b\u65b0\u836fCBT-001\u7b7e\u8ba2\u6388\u6743\u534f\u8bae"},"content":{"rendered":"

\u62e8\u5eb7\u89c6\u4e91\u53ca\u53c2\u5929\u5236\u836f\u5ba3\u5e03\u5c31\u7ffc\u72b6\u80ec\u8089\u521b\u65b0\u836fCBT-001\u7b7e\u8ba2\u6388\u6743\u534f\u8bae <\/strong>a topical treatment of pterygium<\/strong><\/p>\n

 <\/p>\n

2024\u5e748\u67086\u65e5 - [\u4e2d\u56fd\u9999\u6e2f] \u56fd\u9645\u4e34\u5e8a\u773c\u79d1\u836f\u7269\u516c\u53f8Cloudbreak Pharma Inc.(\u603b\u90e8\uff1a\u7f8e\u56fd\u52a0\u5dde\uff1b\u4ee5\u4e0b\u7b80\u79f0\u201c\u62e8\u5eb7\u89c6\u4e91\u201d\uff09\u4e0e\u4e13\u7cbe\u773c\u79d1\u4f01\u4e1a\u53c2\u5929\u5236\u836f\u682a\u5f0f\u4f1a\u793e\uff08\u603b\u90e8\uff1a\u65e5\u672c\u5927\u962a\uff1b\u4ee5\u4e0b\u7b80\u79f0\u201c\u53c2\u5929\u5236\u836f\u201d\uff09\u5ba3\u5e03\u7b7e\u7f72\u4e86\u4e00\u9879\u6388\u6743\u534f\u8bae\uff0c\u62e8\u5eb7\u89c6\u4e91\u5c06\u5176\u6b63\u5728\u7814\u53d1\u7684\u7528\u4e8e\u7ffc\u72b6\u80ec\u8089\u6cbb\u7597\u7684\u591a\u6fc0\u9176\u6291\u5236\u5242CBT-001\uff0c\u6388\u6743\u4e8e\u53c2\u5929\u5236\u836f\uff0c\u8be5\u6388\u6743\u6d89\u53ca\u65e5\u672c\u3001\u97e9\u56fd\u3001\u8d8a\u5357\u3001\u6cf0\u56fd\u3001\u9a6c\u6765\u897f\u4e9a\u3001\u83f2\u5f8b\u5bbe\u3001\u65b0\u52a0\u5761\u548c\u5370\u5ea6\u5c3c\u897f\u4e9a\u5728\u5185\u7684\u4e1c\u5357\u4e9a\u5730\u533a\uff08\u4ee5\u4e0b\u7b80\u79f0\u201c\u5730\u533a\u201d\uff09\u3002\u6839\u636e\u534f\u8bae\u6761\u6b3e\uff0c\u62e8\u5eb7\u89c6\u4e91\u6388\u6743\u53c2\u5929\u5236\u836f\u5728\u8be5\u5730\u533a\u5f00\u53d1\u3001\u751f\u4ea7\u548c\u5546\u4e1a\u5316CBT-001\u836f\u54c1\u3002<\/p>\n

 <\/p>\n

CBT-001\u662f\u62e8\u5eb7\u89c6\u4e91\u7814\u53d1\u7684\u4e00\u79cd\u4e73\u5316\u578b\u5c3c\u8fbe\u5c3c\u5e03\u6ef4\u773c\u6db2\uff0c\u4e3b\u8981\u7528\u4e8e\u6cbb\u7597\u7ffc\u72b6\u80ec\u8089\u3002\u5c3c\u8fbe\u5c3c\u5e03\u662f\u4e00\u79cd\u591a\u6fc0\u9176\u6291\u5236\u5242\uff0c\u4e3b\u8981\u7528\u4e8eVEGF\uff08\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\uff09\u53d7\u4f53\u3001PDGF\uff08\u8840\u5c0f\u677f\u884d\u751f\u751f\u957f\u56e0\u5b50\uff09\u53d7\u4f53\u548cFGF\uff08\u6210\u7ea4\u7ef4\u7ec6\u80de\u751f\u957f\u56e0\u5b50\uff09\u53d7\u4f53\uff0c\u4ece\u800c\u6291\u5236\u8840\u7ba1\u65b0\u751f\u548c\u7ea4\u7ef4\u5316\u3002CBT-001\u5728\u7f8e\u56fd\u5b8c\u6210\u4e86II\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u76ee\u524d\u6b63\u5728\u7f8e\u56fd\u3001\u4e2d\u56fd\u3001\u6fb3\u6d32\u3001\u65b0\u897f\u5170\u548c\u5370\u5ea6\u5f00\u5c55\u5927\u89c4\u6a21\u7684\u5168\u7403\u591a\u4e2d\u5fc3III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002CBT-001\u80fd\u901a\u8fc7\u6ef4\u773c\u6db2\u7684\u65b9\u5f0f\u4e3a\u533b\u751f\u548c\u60a3\u8005\u63d0\u4f9b\u4e00\u79cd\u65b0\u7684\u7ffc\u72b6\u80ec\u8089\u6cbb\u7597\u9009\u62e9\uff0c\u6291\u5236\u75c5\u60c5\u53d1\u5c55\u3002<\/p>\n

 <\/p>\n

\u7ffc\u72b6\u80ec\u8089\u662f\u4e00\u79cd\u773c\u8868\u7684\u975e\u6076\u6027\u7684\u7ea4\u7ef4\u8840\u7ba1\u7ec4\u7ec7\u5f02\u5e38\u589e\u751f\uff0c\u589e\u751f\u4ece\u7403\u7ed3\u819c\u5f00\u59cb\u5e76\u5ef6\u4f38\u81f3\u89d2\u819c\u8868\u9762\u3002\u7ffc\u72b6\u80ec\u8089\u5177\u6709\u4fb5\u5165\u6027\u7684\u751f\u957f\u8d8b\u52bf\uff0c\u4e14\u5177\u6709\u590d\u53d1\u503e\u5411\u548c\u975e\u8f6c\u79fb\u6027\u3002\u5c3d\u7ba1\u7ffc\u72b6\u80ec\u8089\u662f\u975e\u6076\u6027\u7684\uff0c\u4f46\u5b83\u53ef\u80fd\u5f15\u8d77\u660e\u663e\u7684\u773c\u90e8\u75c7\u72b6\uff0c\u5305\u62ec\u5145\u8840\u3001\u523a\u6fc0\u3001\u75bc\u75db\u548c\u5f02\u7269\u611f\uff0c\u4ece\u800c\u5f71\u54cd\u60a3\u8005\u7684\u751f\u6d3b\u3002\u76ee\u524d\uff0c\u5e02\u573a\u4e0a\u5c1a\u65e0\u6279\u51c6\u7684\u6cbb\u7597\u7ffc\u72b6\u80ec\u8089\u836f\u7269\uff0c\u533b\u751f\u901a\u5e38\u4f1a\u4f7f\u7528\u672a\u6709\u4e34\u5e8a\u8bd5\u9a8c\u8ba4\u53ef\u7684\u4eba\u5de5\u6cea\u6db2\u548c\u77ed\u671f\u5c40\u90e8\u773c\u7528\u7c7b\u56fa\u9187\u5f53\u4f5c\u5904\u65b9\u3002\u7136\u800c\uff0c\u8fd9\u4e9b\u836f\u7269\u5728\u957f\u671f\u4f7f\u7528\u4e2d\u53ef\u80fd\u65e0\u6548\u6216\u4e0d\u5b89\u5168\u3002\u5f53\u7ffc\u72b6\u80ec\u8089\u4fb5\u5165\u89c6\u8f74\u6216\u8005\u6301\u7eed\u5145\u8840\u65f6\uff0c\u901a\u5e38\u9700\u8981\u8fdb\u884c\u624b\u672f\u5207\u9664\u3002\u867d\u7136\u6709\u591a\u79cd\u624b\u672f\u65b9\u6cd5\uff0c\u5982\u8f6c\u4f4d\u672f\u548c\u7ed3\u819c\u74e3\u79fb\u690d\uff0c\u4f46\u6240\u6709\u65b9\u6cd5\u90fd\u6709\u590d\u53d1\u7684\u503e\u5411\uff0c1<\/sup>\u8fd9\u88ab\u89c6\u4e3a\u7ffc\u72b6\u80ec\u8089\u624b\u672f\u4e2d\u7684\u95ee\u9898\u3002\u7531\u4e8e\u7d2b\u5916\u7ebf\u4e0e\u8fd9\u79cd\u75be\u75c5\u7684\u75c5\u53d1\u548c\u8fdb\u5c55\u76f8\u5173\uff0c\u7ffc\u72b6\u80ec\u8089\u60a3\u8005\u6700\u5e38\u89c1\u4e8e\u4f4e\u7eac\u5ea6\u7684\u9633\u5149\u5145\u6c9b\u5730\u533a\u3002\u6709\u7814\u7a76\u8868\u660e\uff0c\u5168\u7403\u7ea610%\u7684\u4eba\u53e3\u53d7\u6b64\u5f71\u54cd\uff0c\u5728\u65e5\u672c\u7ea6\u6709400\u4e07\u60a3\u8005\u30022<\/sup>\u5728\u65e5\u672c\uff0c3<\/sup>40\u5c81\u4ee5\u4e0a\u4eba\u7fa4\u4e2d\u7ffc\u72b6\u80ec\u8089\u7684\u60a3\u75c5\u7387\u4f30\u8ba1\u4e3a4%,4<\/sup>\u8be5\u4eba\u7fa4\u5728\u97e9\u56fd\u4e3a3.8%\uff0c5<\/sup>\u5728\u8d8a\u5357\u30016<\/sup>\u9a6c\u6765\u897f\u4e9a\u3001\u83f2\u5f8b\u5bbe\u548c\u6cf0\u56fd\u4e3a10.1%\u30027<\/sup>.<\/p>\n

 <\/p>\n

\u53c2\u5929\u5236\u836f\u9996\u5e2d\u8fd0\u8425\u5b98\u4e2d\u5c9b\u7406\u6075\u8868\u793a\uff1a\u201c\u957f\u671f\u4ee5\u6765\uff0c\u7ffc\u72b6\u80ec\u8089\u4e3b\u8981\u901a\u8fc7\u624b\u672f\u8fdb\u884c\u6cbb\u7597\u3002\u6211\u4eec\u5f88\u9ad8\u5174\u80fd\u4e0e\u62e8\u5eb7\u89c6\u4e91\u5408\u4f5c\uff0c\u5728\u65e5\u672c\u548c\u4e1c\u5357\u4e9a\u5730\u533a\u5f00\u53d1\u5e76\u63a8\u51faCBT-001\u3002\u8fd9\u79cd\u6ef4\u773c\u6db2\u5f62\u5f0f\u7684\u521b\u65b0\u7597\u6cd5\u6709\u671b\u4e3a\u7ffc\u72b6\u80ec\u8089\u60a3\u8005\u63d0\u4f9b\u5168\u65b0\u7684\u6cbb\u7597\u9009\u62e9\u3002\u5c06CBT-001\u7eb3\u5165\u6211\u4eec\u7684\u7814\u53d1\u7ba1\u7ebf\u4e0d\u4ec5\u80fd\u9020\u798f\u5168\u7403\u7ffc\u72b6\u80ec\u8089\u60a3\u8005\uff0c\u8fd8\u4f53\u73b0\u4e86\u6211\u4eec\u4f5c\u4e3a\u773c\u79d1\u9886\u57df\u4e13\u7cbe\u4f01\u4e1a\u52c7\u4e8e\u6311\u6218\u65b0\u9886\u57df\u7684\u51b3\u5fc3\u3002\u6211\u4eec\u5c06\u7ee7\u7eed\u4ece\u60a3\u8005\u89d2\u5ea6\u51fa\u53d1\uff0c\u81f4\u529b\u4e8e\u586b\u8865\u533b\u7597\u9700\u6c42\u7684\u7a7a\u767d\uff0c\u63d0\u4f9b\u66f4\u591a\u65b0\u578b\u6cbb\u7597\u65b9\u6848\u3002\u201d<\/p>\n

 <\/p>\n

\u62e8\u5eb7\u89c6\u4e91\u521b\u59cb\u4eba\u517c\u9996\u5e2d\u6267\u884c\u5b98\u502a\u52b2\u677e\u535a\u58eb\u8868\u793a\uff1a\u201c\u6211\u4eec\u975e\u5e38\u9ad8\u5174\u80fd\u4e0e\u53c2\u5929\u5236\u836f\u5c55\u5f00\u5408\u4f5c\u3002\u53c2\u5929\u5236\u836f\u4e00\u76f4\u628a\u75c5\u4eba\u7684\u773c\u90e8\u5065\u5eb7\u653e\u5728\u9996\u4f4d\uff0c\u5176\u5bf9\u521b\u65b0\u548c\u8d28\u91cf\u7684\u8ffd\u6c42\u95fb\u540d\u4e1a\u5185\u3002\u8fd9\u6b21\u5408\u4f5c\u5145\u5206\u53d1\u6325\u4e86\u53cc\u65b9\u7684\u4f18\u52bf\uff0c\u4e3a\u5b9e\u73b0\u6211\u4eec\u7684\u76ee\u6807\u5960\u5b9a\u4e86\u575a\u5b9e\u57fa\u7840\u3002\u6211\u4eec\u671f\u5f85\u80fd\u5c3d\u5feb\u5c06\u8fd9\u9879\u521b\u65b0\u6027\u7684\u4ea7\u54c1\u63a8\u5411\u5e02\u573a\uff0c\u9020\u798f\u65e5\u672c\u4e43\u81f3\u5168\u7403\u7684\u7ffc\u72b6\u80ec\u8089\u60a3\u8005\u3002\u201d<\/p>\n

 <\/p>\n

\u6839\u636e\u534f\u8bae\uff0c\u62e8\u5eb7\u89c6\u4e91\u5c06\u83b7\u5f97\u603b\u989d\u9ad8\u8fbe9100\u4e07\u7f8e\u5143\u7684\u9996\u4ed8\u6b3e\u53ca\u91cc\u7a0b\u7891\u4ed8\u6b3e\u3002\u6b64\u5916\uff0c\u62e8\u5eb7\u89c6\u4e91\u8fd8\u5c06\u83b7\u5f97\u4ea7\u54c1\u672a\u6765\u51c0\u9500\u552e\u989d\u7684\u4e24\u4f4d\u6570\u767e\u5206\u6bd4\uff0c\u4f5c\u4e3a\u8be5\u4ea7\u54c1\u7684\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/p>\n

 <\/p>\n

\u672c\u65b0\u95fb\u7a3f\u7531Cloudbreak Pharma Inc.\u53ca\u53c2\u5929\u5236\u836f\u682a\u5f0f\u4f1a\u793e\u8054\u5408\u53d1\u5e03\u3002<\/p>\n

 <\/p>\n

References<\/strong><\/p>\n

    \n
  1. Tanaka et al, Journal of Japanese Ophthalmology 115:386-390, 2011<\/li>\n
  2. Modenese et al, Int J Environ Res Public Health 15(1):37 (2018)<\/li>\n
  3. Liu L et al. Geographical prevalence and risk factors for pterygium: a systematic review and meta-analysis. BMJ Open 2013;3:e003787. doi:10.1136\/bmjopen-2013-003787<\/li>\n
  4. Estimated from epidemiological studies (4.4% (Minamiaizu Town, Fukushima Prefecture, 37\u00b0N) of those aged 40 and over and 7.2% (Monzen Town, Ishikawa Prefecture, 37\u00b0N) of those aged 50 and over)<\/li>\n
  5. Tano et al, Acta Ophthalmol 91(3):e232-6, 2013<\/li>\n
  6. Rim TH et al, PLOS One 12(3) e0171954, 2017<\/li>\n
  7. Ang M et al, Ophthalmology 119(8):1509e15, 2012<\/li>\n<\/ol>\n

     <\/p>\n

     <\/p>\n

    \u5173\u4e8eCloudbreak Pharma Inc.<\/u><\/strong><\/p>\n

    \u201c\u62e8\u5eb7\u89c6\u4e91\u201d\uff0c\u662f\u4e00\u5bb6\u521b\u65b0\u9a71\u52a8\u7684\u4e34\u5e8a\u773c\u79d1\u751f\u7269\u6280\u672f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u5f00\u53d1\u521b\u65b0\u6027\u53ca\u5dee\u5f02\u5316\u7597\u6cd5\u3002\u62e8\u5eb7\u89c6\u4e91\u4e8e2015\u5e74\u5728\u7f8e\u56fd\u6210\u7acb\uff0c\u9664\u8bbe\u7acb\u5728\u52a0\u5dde\u5c14\u6e7e\u7684\u603b\u90e8\u5916\uff0c\u5728\u4e2d\u56fd\u5927\u9646\u548c\u4e2d\u56fd\u9999\u6e2f\u4e5f\u6709\u5efa\u7acb\u5206\u90e8\u3002\u6211\u4eec\u81f4\u529b\u4e8e\u81ea\u4e3b\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u56fd\u9645\u9996\u521b\u6216\u8005\u540c\u7c7b\u4e2d\u6700\u4f73\u7684\u773c\u79d1\u65b0\u836f\uff0c\u4ee5\u89e3\u51b3\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\u3002\u62e8\u5eb7\u89c6\u4e91\u5df2\u5efa\u7acb\u4e86\u5e7f\u6cdb\u4e14\u521b\u65b0\u7684\u7ba1\u7ebf\u5305\u62ec\u516b\u79cd\u836f\u7269\u5019\u9009\u7269\uff0c\u6db5\u76d6\u773c\u7403\u524d\u540e\u90e8\u7684\u4e3b\u8981\u75be\u75c5\uff0c\u5176\u4e2d\u56db\u6b3e\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\uff0c\u56db\u6b3e\u5904\u4e8e\u4e34\u5e8a\u524d\u9636\u6bb5\u3002\u6211\u4eec\u7684\u4f7f\u547d\u662f\u5e2e\u52a9\u4e16\u754c\uff1a\u201cSeeing Life Better Through Medicine\uff02\uff61<\/p>\n

    \u6b32\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u53c2\u8003\u62e8\u5eb7\u89c6\u4e91\u7684\u7f51\u7ad9 https:\/\/cloudbreakpharma.com\/<\/a><\/p>\n

     <\/p>\n

    \u00a0<\/u><\/strong><\/p>\n

    \u5173\u4e8e\u53c2\u5929\u5236\u836f\u682a\u5f0f\u4f1a\u793e<\/u><\/strong><\/p>\n

    \u5173\u4e8e\u53c2\u5929\u5236\u836f\u682a\u5f0f\u4f1a\u793e\n\u53c2\u5929\u4f5c\u4e3a\u4e00\u5bb6\u4e13\u6ce8\u4e8e\u89c6\u89c9\u5065\u5eb7\u7684\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u900f\u8fc7\u4e3a\u5168\u7403\u7684\u60a3\u8005\u3001\u6d88\u8d39\u8005\u4ee5\u53ca\u533b\u7597\u4eba\u5458\u63d0\u4f9b\u6709\u4ef7\u503c\u7684\u4ea7\u54c1\u548c\u670d\u52a1\uff0c\u4ee5\u5b9e\u73b0\u6bcf\u4e2a\u4eba\u7684\u201cHappiness with Vision\u201d\u3002\u6210\u7acb140\u5e74\u4ee5\u6765\uff0c\u5728\u6838\u5fc3\u7406\u5ff5\u201c\u5929\u673a\u306b\u53c2\u4e0e\u3059\u308b\u201d\uff08\u4e2d\u6587\uff1a\u53c2\u609f\u5929\u5730\u4e07\u7269\u4e4b\u89c4\u5f8b\uff0c\u4e3a\u589e\u8fdb\u4eba\u7c7b\u5065\u5eb7\u505a\u51fa\u8d21\u732e\uff09\u7684\u6307\u5f15\u4e0b\uff0c\u53c2\u5929\u5236\u836f\u81f4\u529b\u4e8e\u5e2e\u52a9\u4eba\u4eec\u7ef4\u62a4\u548c\u6539\u5584\u773c\u5065\u5eb7\u3002\u53c2\u5929\u5236\u836f\u4ece\u4e8b\u773c\u79d1\u4fdd\u5065\u9886\u57df\u7684\u5168\u7403\u7814\u7a76\u548c\u5f00\u53d1\u3001\u5236\u9020\u4ee5\u53ca\u836f\u54c1\u7684\u9500\u552e\u548c\u8425\u9500\uff0c\u4e3a\u5168\u740360\u591a\u4e2a\u56fd\u5bb6\u548c\u5730\u533a\u7ea65000\u4e07\u4eba\u7684\u773c\u5065\u5eb7\u4fdd\u9a7e\u62a4\u822a\u3002\u53c2\u5929\u7684\u804c\u8d23\u662f\u5229\u7528\u6211\u4eec\u5728\u773c\u79d1\u533b\u7597\u9886\u57df\u7684\u4e13\u4e1a\u77e5\u8bc6\uff0c\u4ece\u60a3\u8005\u89d2\u5ea6\u51fa\u53d1\uff0c\u521b\u9020\u5404\u79cd\u4ea7\u54c1\u548c\u670d\u52a1\uff0c\u6301\u7eed\u4e0d\u65ad\u5730\u4e3a\u60a3\u8005\u548c\u793e\u4f1a\u63d0\u4f9b\u65b0\u4ef7\u503c\uff0c\u5e76\u5728\u773c\u90e8\u75be\u75c5\u9884\u9632\u3001\u8bca\u65ad\u548c\u6cbb\u7597\u7b49\u65b9\u9762\u63a2\u7d22\u548c\u63d0\u4f9b\u91cd\u8981\u7684\u65b0\u4ef7\u503c\u3002\u4e3a\u8ba9\u5c3d\u53ef\u80fd\u591a\u7684\u60a3\u8005\u548c\u6d88\u8d39\u8005\u80fd\u5728\u672a\u6765\u8fc7\u4e0a\u5e78\u798f\u7f8e\u6ee1\u7684\u751f\u6d3b\uff0c\u53c2\u5929\u5236\u836f\u5c06\u5168\u529b\u4ee5\u8d74\uff0c\u5e0c\u671b\u900f\u8fc7\u521b\u9020\u6700\u4f73\u7684\u89c6\u89c9\u4f53\u9a8c\uff0c\u8ba9\u6bcf\u4e2a\u4eba\u62e5\u6709\u6700\u5e78\u798f\u7684\u751f\u6d3b\u3002<\/p>\n

    For more information, please visit Santen\u2019s website https:\/\/www.santen.com\/en<\/a>.<\/p>\n

    \u00a0<\/strong><\/p>\n

    \u00a0<\/strong><\/p>\n

    \u8054\u7edc\u6211\u4eec<\/strong><\/p>\n

    Corporate Communications<\/p>\n

    \u53c2\u5929\u5236\u836f\u682a\u5f0f\u4f1a\u793e<\/p>\n

    E-mail: communication@santen.com<\/a><\/p>\n

     <\/p>\n

    Corporate Communications Department<\/p>\n

    Cloudbreak Pharma Inc.<\/p>\n

    E-mail\u00a0: HongKongPR@cloudbreakpharma.com<\/a><\/p>\n

    Tel +852-2882-6582<\/p>\n

     <\/p>\n

    \u58f0\u660e\uff1a\u672c\u65b0\u95fb\u7a3f\u5df2\u4ee5\u65e5\u8bed\u3001\u7e41\u4f53\u4e2d\u6587\u3001\u7b80\u4f53\u4e2d\u6587\u548c\u82f1\u6587\u53d1\u5e03\u3002\u5982\u5404\u8bed\u8a00\u7248\u672c\u6709\u4efb\u4f55\u4e0d\u4e00\u81f4\u4e4b\u5904\uff0c\u5e94\u4ee5\u82f1\u6587\u7248\u672c\u4e3a\u51c6\u3002<\/em><\/p>","protected":false},"excerpt":{"rendered":"

    Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium   6 August 2024 \u2013 Osaka, Japan \u2013 Santen Pharmaceutical Co., Ltd. (head office: Osaka, Japan; hereinafter Santen), a specialist in ophthalmology, and Cloudbreak Pharma Inc. (head office: California, US; hereinafter Cloudbreak), a clinical stage ophthalmic drug company, announce the […]<\/p>\n","protected":false},"author":16,"featured_media":863,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-862","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"\nSanten and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium - Cloudbreak Pharma, Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cloudbreakpharma.com\/zh\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium - Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"og:description\" content=\"Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium   6 August 2024 \u2013 Osaka, Japan \u2013 Santen Pharmaceutical Co., Ltd. (head office: Osaka, Japan; hereinafter Santen), a specialist in ophthalmology, and Cloudbreak Pharma Inc. (head office: California, US; hereinafter Cloudbreak), a clinical stage ophthalmic drug company, announce the […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cloudbreakpharma.com\/zh\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/\" \/>\n<meta property=\"og:site_name\" content=\"Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-06T06:06:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-06T06:14:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2024\/08\/\u5fae\u4fe1\u622a\u56fe_20240806105952.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1020\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"James Gilbert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"James Gilbert\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/\"},\"author\":{\"name\":\"James Gilbert\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/9233f32eb4e35bf16080d902fbbd20d3\"},\"headline\":\"Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium\",\"datePublished\":\"2024-08-06T06:06:36+00:00\",\"dateModified\":\"2024-08-06T06:14:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/\"},\"wordCount\":1171,\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/\u5fae\u4fe1\u622a\u56fe_20240806105952.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"zh-CN\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/\",\"name\":\"Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium - Cloudbreak Pharma, Inc.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/\u5fae\u4fe1\u622a\u56fe_20240806105952.jpg\",\"datePublished\":\"2024-08-06T06:06:36+00:00\",\"dateModified\":\"2024-08-06T06:14:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/#breadcrumb\"},\"inLanguage\":\"zh-CN\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/\u5fae\u4fe1\u622a\u56fe_20240806105952.jpg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/\u5fae\u4fe1\u622a\u56fe_20240806105952.jpg\",\"width\":1020,\"height\":416},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"name\":\"Cloudbreak Pharma, Inc.\",\"description\":\"Seeing Life Better Through Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cloudbreakpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-CN\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\",\"name\":\"Cloudbreak Pharma, Inc.\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"width\":824,\"height\":199,\"caption\":\"Cloudbreak Pharma, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/9233f32eb4e35bf16080d902fbbd20d3\",\"name\":\"James Gilbert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"caption\":\"James Gilbert\"},\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/zh\\\/author\\\/jgdm18gmail-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium - Cloudbreak Pharma, Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cloudbreakpharma.com\/zh\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/","og_locale":"zh_CN","og_type":"article","og_title":"Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium - Cloudbreak Pharma, Inc.","og_description":"Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium   6 August 2024 \u2013 Osaka, Japan \u2013 Santen Pharmaceutical Co., Ltd. (head office: Osaka, Japan; hereinafter Santen), a specialist in ophthalmology, and Cloudbreak Pharma Inc. (head office: California, US; hereinafter Cloudbreak), a clinical stage ophthalmic drug company, announce the […]","og_url":"https:\/\/cloudbreakpharma.com\/zh\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/","og_site_name":"Cloudbreak Pharma, Inc.","article_published_time":"2024-08-06T06:06:36+00:00","article_modified_time":"2024-08-06T06:14:21+00:00","og_image":[{"width":1020,"height":416,"url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2024\/08\/\u5fae\u4fe1\u622a\u56fe_20240806105952.jpg","type":"image\/jpeg"}],"author":"James Gilbert","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"James Gilbert","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"6 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/#article","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/"},"author":{"name":"James Gilbert","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/9233f32eb4e35bf16080d902fbbd20d3"},"headline":"Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium","datePublished":"2024-08-06T06:06:36+00:00","dateModified":"2024-08-06T06:14:21+00:00","mainEntityOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/"},"wordCount":1171,"publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2024\/08\/\u5fae\u4fe1\u622a\u56fe_20240806105952.jpg","articleSection":["News"],"inLanguage":"zh-CN"},{"@type":"WebPage","@id":"https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/","url":"https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/","name":"Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium - Cloudbreak Pharma, Inc.","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/#primaryimage"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2024\/08\/\u5fae\u4fe1\u622a\u56fe_20240806105952.jpg","datePublished":"2024-08-06T06:06:36+00:00","dateModified":"2024-08-06T06:14:21+00:00","breadcrumb":{"@id":"https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/#breadcrumb"},"inLanguage":"zh-CN","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/"]}]},{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/#primaryimage","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2024\/08\/\u5fae\u4fe1\u622a\u56fe_20240806105952.jpg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2024\/08\/\u5fae\u4fe1\u622a\u56fe_20240806105952.jpg","width":1020,"height":416},{"@type":"BreadcrumbList","@id":"https:\/\/cloudbreakpharma.com\/santen-and-cloudbreak-execute-a-new-licensing-agreement-for-cbt-001-a-topical-treatment-of-pterygium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cloudbreakpharma.com\/"},{"@type":"ListItem","position":2,"name":"Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium"}]},{"@type":"WebSite","@id":"https:\/\/cloudbreakpharma.com\/#website","url":"https:\/\/cloudbreakpharma.com\/","name":"Cloudbreak Pharma, Inc.","description":"\u533b\u836f\u4f7f\u6211\u4eec\u80fd\u66f4\u597d\u7684\u89c6\u89c9\u4eab\u53d7\u751f\u6d3b","publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cloudbreakpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-CN"},{"@type":"Organization","@id":"https:\/\/cloudbreakpharma.com\/#organization","name":"Cloudbreak Pharma, Inc.","url":"https:\/\/cloudbreakpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","width":824,"height":199,"caption":"Cloudbreak Pharma, Inc."},"image":{"@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/9233f32eb4e35bf16080d902fbbd20d3","name":"James Gilbert","image":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","caption":"James Gilbert"},"url":"https:\/\/cloudbreakpharma.com\/zh\/author\/jgdm18gmail-com\/"}]}},"_links":{"self":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/comments?post=862"}],"version-history":[{"count":0,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/862\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media\/863"}],"wp:attachment":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media?parent=862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/categories?post=862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/tags?post=862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}